= Emerging. More than 5 years before clinical availability. (26.55%)
= Expected to be clinically available in 1 to 4 years. (39.66%)
= Clinically available now. (33.79%)
MSACL 2020 US : Ekroos

MSACL 2020 US Abstract

Topic: Lipidomics

Podium Presentation in Room 2 on Wednesday at 9:20 (Chair: Melanie Odenkirk)

Development of Clinical Lipidomics Accompanied with Standardization and Harmonization by the International Lipidomics Society (ILS)

Kim Ekroos (Presenter)
Lipidomics Consulting Ltd

Presenter Bio(s): Dr. Kim Ekroos obtained his Ph.D. in biology from the Technical University in Dresden, Germany, in 2003. Today, he runs his own consulting business, providing unique consulting services for customers globally in the field of lipidomics. He has indefatigably focused on lipidomics, with prime interest in developing and utilizing novel mass spectrometry high-throughput technologies for the precise assessment of lipidomes enabled by advanced mass spectrometry, automation and software tools, and one of the pioneers in bringing the first lipidomics-based biomarkers into clinics. He is a member of the European Lipidomics Meeting committee, co-founder of the lipidomics standards initiative and the president of the International Lipidomics Society (https://lipidomicssociety.org).

Authors: Kim Ekroos (1), Gerhard Liebisch (2), Michal HolĨapek (3), Robert Ahrends (4), Harald Köfeler (5), Xianlin Han (6) and Markus Wenk (7)
(1) Lipidomics Consulting Ltd, Esbo, Finland (2) Institute of Clinical Chemistry and Laboratory Medicine, University of Regensburg, Germany (3) Department of Analytical Chemistry, Faculty of Chemical Technology, University of Pardubice, Czech Republic (4) Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Währingerstr. 38, A-1090 Wien, Austria (5) Core Facility for Mass Spectrometry and Lipidomics, Medical University of Graz, Austria (6) Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, TX, USA (7) Singapore Lipidomics Incubator (SLING), Department of Biochemistry, YLL School of Medicine, National University of Singapore

Abstract

INTRODUCTION: Lipid metabolism is tightly regulated to maintain homeostasis. Loss of control can result in unwanted cascades of biological events triggering deleterious pathophysiological conditions. The evolution of lipidomics technologies is set to tackle this problem, driven by high expectation in its ability to afford new opportunities for studying lipids in health and disease, and put forward new biomarker candidates. However, many studies differ vastly in methodologies, workflows and data presentation and do not report absolute lipid concentrations, hampering a successful transition of lipidomics into the clinical landscape.

OBJECTIVES: Our prime objective was to identify a solution aiming to harmonize and standardize the field of lipidomics.

METHODS: We performed exhaustive discussions, presentations and workshops through-out the lipidomics community to identify the current gaps and needs.

RESULTS: We have established the International Lipidomics Society (ILS) flagship, fostering international community-wide coordination and communication for the creation of lipidomics specific guidelines for good scientific practice and future development. A central focus lies, among others, in the engagements of working groups actively developing lipidomics standards guidelines, reference materials, clinical lipidomics, and a close crosstalk to lipid biology and medicine.

CONCLUSIONS: ILS is the point of contact for lipidomics research, development and commercialization, and actively guiding the developments closer towards the clinical arena.


Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no